Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

BIX 02565

Catalog No: tcsc1659

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1311367-27-7

Formula:
$C_{26}H_{30}N_6O_2$

Pathway:
MAPK/ERK Pathway

Target:
Ribosomal S6 Kinase (RSK)

Purity / Grade:
>98%

Solubility:
DMSO : 20.75 mg/mL (45.25 mM; Need ultrasonic and warming)

Observed Molecular Weight:
458.56

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

BIX 02565 is a potent ribosomal S6 kinase 2 (**RSK2**) inhibitor with **IC_{50}** of 1.1 nM.

IC50 & Target: IC50: 1.1 nM (RSK2)[1]

In Vitro: BIX 02565, a potent RSK2 inhibitor (IC_{50}=1.1 nM) targets for the treatment of heart failure secondary to myocardial infarction through indirect NHE inhibition[1]. BIX 02565, a second Rsk inhibitor, protects enzyme active sites from reaction with biotinylated nucleotide acyl phosphates[2].

In Vivo: In telemetry-instrumented rats, BIX 02565 (30, 100, and 300 mg/kg p.o. QD for 4 days) elicits concentration-dependent decreases in MAP after each dose (to -39±4 mm Hg on day 4 at T_{max}). BIX 02565 produces concentration-dependent relaxation ex vivo in the phenylephrine-constricted rat aortic ring at concentrations above 0.03 μM with a calculated EC_{50} of 3.1 μM. Subsequently, BIX 02565 is infused in the anesthetized rat in a low-dose (0.1, 0.3, and 1.0 mg/kg per 20 min) and high-dose (1.0, 3.0, and 10.0 mg/kg per 20 min) series of continuous infusions to test the effect of compound on hemodynamics in vivo[1].